Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)

Al­bert Bourla bagged $21M in year marked by gener­ics spin­off, colos­sal R&D ef­fort for Covid-19 vac­cine

Among the largest drug­mak­ers, Pfiz­er had one of the busiest years of its peers, in­clud­ing rac­ing to mar­ket with its BioN­Tech-part­nered Covid-19 shot and suc­cess­ful­ly spin­ning out its gener­ic Up­john unit. For two-year CEO Al­bert Bourla, all that work meant more mon­ey in his pock­et.

Bourla earned a $21 mil­lion pay pack­age in 2020, a rough­ly 17% jump from the $17.9 mil­lion he made the pri­or year. Of that, the biggest bumps were op­tions awards — Bourla took home $6.78 mil­lion in 2020 com­pared with $6.08 mil­lion the year be­fore — and non-eq­ui­ty in­cen­tives, of which Bourla snared $5.5 mil­lion. The year be­fore, that fig­ure was $3.63 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.